Aggressive cancers found more susceptible to combination treatment compared with monotherapy.
Oncology
Advertisement
Stakeholders debate the benefits of direct and indirect remuneration fees.
Advertisement
Certain BRCA1 mutations reduce the risk of developing leukemia.
Onset or rapid deterioration of diabetes may be an indicator of hidden pancreatic cancer.
Top news of the day from across the health care landscape.
Unreliable data found in reports that did not support the professor’s hypothesis in cancer research.
Advertisement
Why are some patients with cancer unresponsive to immunotherapies?
Low-dose computed tomography screenings remained very low and unchanged among eligible individuals.
Study findings shed new light on breast cancer treatments.
ER-positive breast cancers may be producing their own estrogen.
Advertisement
Potential cancer drug class may bump standard practice of 1 drug, 1 target.
Squamous cell carcinoma carries a transcriptional fingerprint of basal cells.
Top news of the week in oncology and cancer drug development.
Interference with transcription factor activity may lead to the development of novel disease therapeutics.
Uterine cancers disseminated by surgical device.
Lung cancer demonstration project examines the feasibility of a screening program for veterans.
Combination treatment reduces head and neck cancer deaths by 20%.
Top news of the day from across the health care landscape.
Top news of the day from across the healthcare landscape.
Hypoxic tumor microenvironments influence the fate of disseminated tumor cells.
University of Wisconsin-Madison investigators create a device to improve cancer detection.
Big data could allow physicians to take action before a patient with cancer needs to visit an emergency hospital.
African Americans with breast cancer have a 40% higher death rate than European-Americans.
Top news of the day from across the health care landscape.
Creating meaningful measurements for cancer care has been difficult.
Common diabetes drug changes the biology of cancer cells.
Time of day is an important factor in chemotherapy-induced adverse events.
Top news of the day from across the health care landscape.
Findings may lead to preventative treatments for breast cancer, such as anti-inflammatory drugs.
Keytruda previously granted breakthrough therapy designation as a second-line treatment for patients with bladder cancer.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Priority Review to Gedatolisib for HR+, HER2-Negative Advanced Breast Cancer
2
Unique Pharmacy Technician Career Ladder Meets the Needs of a Growing Profession
3
Circulating Tumor Cells May Guide Use of Tarlatamab in Small Cell Lung Cancer
4
Pharmacists Can Implement Test-and-Treat Services in Their Practice Settings
5